Search

Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients

Apr. 26, 2018

Ness Ziona, Israel, 26 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the enrollment of the first patient for its clinical trial in ALS patients, using the cell therapy product developed by the company, AstroRx®.


The phase I/IIa clinical trial is being conducted by the Department of Neurology of the Hadassah Ein-Kerem Medical Center, and it is expected to include 21 patients.


The objective of the trial is to evaluate the safety and efficacy of AstroRx® in patients.

Interim results of the trial are expected within the coming year.


Professor Michel Revel, the company's Chief Scientist, said: "Kadimastem's commencement of the clinical trial in ALS, according to the clinical protocol, is a significant milestone in the company's clinical program. Thanks to the full cooperation provided by the physicians responsible for the trial at the Department of Neurology of the Hadassah Medical Center and the teams involved in the trial, the quick enrollment of the first patient was made possible. We strongly believe in the success of the trial according to the set timeframe, for the benefit of the patients."


Yossi Ben-Yossef, CEO of Kadimastem, added: "After obtaining the approval of the Ministry of Health for the AstroRx® clinical trial in ALS patients, Kadimastem quickly organized for the commencement of the trial.  I hope and believe that AstroRx® will likely improve the condition of the patients participating in the trial. In recent years, the cell therapy field has greatly accelerated globally. With the commencement of the clinical trial, Kadimastem joins a select group of biotechnology companies worldwide, that have the know-how and technological capability to bring advanced treatments based on pluripotent stem cells to the clinical trial stage. I believe that the advancement of the clinical program will significantly reinforce Kadimastem and position it as a leading company in the cell therapy field."

© 2020 by Kadimastem

  • White Facebook Icon
  • White Twitter Icon
  • White LinkedIn Icon